Actinic Keratosis Market Size, Growth & Forecast to 2032

Market Insights

• The global market for actinic keratosis is expected to grow from its estimated USD 6514.2 million in 2023 to USD 9933.73 million in 2032 at a compound annual growth rate (CAGR) of 4.80% between 2024 and 2032.
• The largest treatment type category is topical medications. On the other hand, photodynamic therapy (PDT) is expected to grow at a strong CAGR.
• The leading distribution channel segment is hospitals and clinics.
• The CAGR for prescription medications is expected to be the highest during the projection period.
• The outpatient treatment will have the highest CAGR throughout the prediction period.
• The adult age group is estimated to have the greatest CAGR during the forecast period.
• The male category is predicted to grow fastest over the projection period.
• North America dominated the actinic keratosis market.
• Regarding the market share of actinic keratosis, Europe is expected to come second.
• In the actinic keratosis market, Asia Pacific is anticipated to grow fastest.
• The most significant factors supporting the market include expanding actinic keratosis frequency, rising desire for minimally invasive procedures, and expanding research and development for new treatment developments.
• The actinic keratosis market is driven by factors such as the expansion of treatment options, the emergence of targeted therapies, the incorporation of digital health solutions, and the exploration of nutritional supplements.

Executive Summary

Market Definition

The actinic keratosis market is the pharmaceutical and healthcare sector area dedicated to actinic keratosis (AK) diagnosis, treatment, and management. An aberrant cell growth brought on by chronic UV exposure is known as actinic keratosis. By freezing them with liquid nitrogen, actinic keratoses can be eliminated. The application of cryotherapy is advised for the treatment of individual AK lesions. On the other hand, topical medical therapies, also known as field therapy, are utilized to treat several lesions on a single sun-damaged area, with the added benefit of emphasizing and treating invisible lesions.

Market Overview

The actinic keratosis sector is estimated to develop at a 4.80% compound annual growth rate (CAGR) between 2024 and 2032, maintaining its current upward trend. The market will keep developing, rising from its estimated value of USD 6514.2 million in 2023 to USD 9933.73 million in 2032.

Some primary factors contributing to the market include escalating actinic keratosis occurrence, climbing interest in minimally invasive operations, and improving research and development for fresh treatment advancements. As per the April 2022 publication in the Indian Journal of Dermatology, actinic keratosis is an often observed symptom in the outpatient context, with over 10% of dermatology visits resulting in a diagnosis. In the United Kingdom, actinic keratosis lesions affect 15%–23% of the population; among those over 50, this number rises to 37.5%. This will probably boost the uptake of current treatments and promote early disease detection. Additionally, a June 2022 MDPI paper states that 5-aminolevulinic acid (5-ALA) photodynamic therapy (PDT) is a newly available therapeutic option for actinic keratosis. Throughout the projected period, the rise in minimally invasive treatments like photodynamic therapy brought about by the rise in actinic keratosis prevalence is anticipated to support the market expansion.

The significant market participants' most recent product launches also contribute to the market's expansion. For example, Biofrontera Inc. initiated a multicenter, randomized, double-blind, vehicle-controlled Phase 3 clinical research in November 2022 to assess the safety and effectiveness of Ameluz and BF-RhodoLED XL in the field-directed therapy for actinic keratosis (AK) on the trunk, neck, and extremities. Moreover, Almirall, S.A. introduced Klisyri (tirbanibulin) in Germany and the United Kingdom in September 2021. The Medicines & Healthcare Products Regulatory Agency (MHRA) in the United Kingdom and the European Commission approved the medicine before it may be sold to people with actinic keratosis of the scalp and face.

Segmentation by Treatment Type

• Based on the kind of treatment, topical medications lead the market. Topical medications are administered topically (to the skin or eyes) to produce the intended local therapeutic effect. Considering how efficiently the skin acts as a barrier, topical medicine administration is particularly stressful.
• The photodynamic therapy (PDT) category will exhibit a sizable CAGR during the projected period. The medical procedure known as photodynamic therapy uses a photosensitizing agent activated by light to target and kill aberrant cells. PDT is a viable therapeutic option for Actinic Keratosis (AK) to treat this precancerous skin condition.
• Other treatment types, including cryotherapy, laser therapy, and chemical peels, additionally support the need for actinic keratosis.

Segmentation by Distribution channel

• The main distribution channels are hospitals and clinics. Providing patients with prescribed medications, such as topical creams and ointments used in treating actinic keratosis, is a crucial function of hospitals and clinics offering pharmacy services in the actinic keratosis market.
• The dermatology centers category will likely register a significant CAGR during forecasting. A variety of treatment options are available for actinic keratosis at dermatology centers. Topical medicines, cryotherapy (freezing), laser therapy, photodynamic therapy, chemical peels, and surgical excision in certain situations are a few examples. The severity of AK, the patient's preferences, and other variables influence the treatment option.
• Other distribution channels, such as retail pharmacies and online retail, also contribute to the demand for actinic keratosis.

Segmentation by Prescription Status

• It is projected that the prescription medications category will grow at the fastest rate over the projection period. When it comes to treating actinic keratosis, prescription drugs are essential. Targeting and eliminating abnormal skin cells, which lowers the likelihood of skin cancer developing, is the aim of these medications.
• The need for actinic keratosis is also influenced by other prescription status, including over-the-counter (OTC) Products.

Segmentation by Patient Type

• The outpatient treatment category will likely have the highest CAGR during the projection period. Many non-residential treatments and initiatives are available for outpatient therapy to fulfill the patient's needs. In addition to individual and group counseling, family treatment, crisis intervention, patient education, case management, scheduling therapy, and discharge planning, they are all included in the services provided.
• Other patient type, such as self-administered treatment, also contribute to the demand for actinic keratosis.

Segmentation by Age Group

• The adults will be expected to have the foremost CAGR during the prediction period. Since actinic keratosis is primarily linked to cumulative sun damage, older people who have had years of prolonged sun exposure tend to have higher prevalence rates. The demographic most frequently impacted by this skin condition is reflected in the actinic keratosis market's focus on the adult age group.
• Other age groups, such as the elderly, also contribute to the demand for actinic keratosis.

Segmentation by Gender

• Males will be expected to have the foremost CAGR during the prediction period. The risk of developing AK is 2-3 times higher in men than in women. This could result from fewer sunscreen applications or increased sun exposure at work.
• Other genders, such as females, also contribute to the demand for actinic keratosis.

Segmentation by Region

• North America leads the actinic keratosis market. North America has a highly developed healthcare infrastructure, which includes research institutions, medical technologies, and well-developed healthcare systems. This promotes actinic keratosis early diagnosis, treatment, and detection, which propels market expansion.
• Europe is estimated to rank second in market size for actinic keratosis.
• Asia Pacific will witness the most rapid growth of the actinic keratosis market.
• The remaining requirement for actinic keratosis is covered by world regions such as Africa, the Middle East, and Latin America.

During the projected time, the global actinic keratosis market is anticipated to develop due to high treatment efficiency. Regulatory agencies' expanding approval of products to treat actinic keratosis is expected to encourage the global actinic keratosis market's expansion during the projected period.

Due to the rising incidence of actinic keratosis and the region's larger age demographic, North America is anticipated to account for an enormous portion of the global actinic keratosis market. For example, more than 54 million Americans over 65 live in the United States, making up 16.5% of the country's overall population, according to the 2021 America's Health Rankings data. By 2050, there will likely be 85.7 million adults in the country who are 65 years of age or older, according to projections. Furthermore, a Statistics Canada update indicates that in April 2022, 7.2 million Canadians were 65 years of age or older (19%), and 9.2 million were baby boomers (about 25%) in 2021. Furthermore, the World Bank estimated in January 2023 that 8.13% of Mexicans were 65 years of age or older in 2021.

Throughout the forecast, the actinic keratosis market in Asia-Pacific is anticipated to expand fastest. Actinic keratosis is becoming more common in the Asia-Pacific area as a result of various factors, including pollution from the environment, changing lifestyles, and increased sun exposure. Actinic keratosis treatments are, therefore, in higher demand. The actinic keratosis market is expanding due to an aging population in many Asia Pacific nations. Because actinic keratosis is more common in older people, its prevalence is predicted to increase with aging populations, propelling market growth. The Asia Pacific market has grown due to the availability of cutting-edge actinic keratosis treatment options like topical therapies, cryotherapy, photodynamic therapy, and laser therapy.

Key Highlights of the Report

The global actinic keratosis market is segmented by treatment type, distribution channel, prescription status, patient type, age group, gender, and region. As far as the treatment type is concerned, topical medications are the market spearhead. Hospitals and clinics are the top distribution channel segment. The prescription medications category is anticipated to increase at the highest CAGR throughout the projection period. The outpatient treatment industry will experience the highest CAGR during the forecast period. The actinic keratosis market is expanding mostly in North America.

The significant number of cases of actinic keratosis and the growing acceptance of minimally invasive techniques are the reasons behind the growth of the actinic keratosis market in the United Kingdom. Furthermore, most actinic keratoses are treated initially with minimally invasive operations. Several other factors will contribute to the market's development and enhance demand for actinic keratosis therapies, including affordable treatment options and favorable Medicaid and Medicare reimbursements.

North America is expected to account for the largest portion of the actinic keratosis market globally. The market continues to expand due to the participants' recent partnerships, launches, and activities. For example, Almirall introduced tirbanibulin (Klisyri, Almirall), a new microtubule inhibitor, to the US market in February 2021 for the topical treatment of actinic keratosis (AK) of the face and scalp. It is anticipated that this development will propel the Actinic Keratosis market's expansion in North America. The Asia Pacific region is also assumed to have the market's sharpest growth. Skin diseases such as actinic keratosis are becoming more common in the Asia Pacific area. The prevalence of actinic keratosis is on the rise due to factors like aging populations, population growth, and increased exposure to UV radiation.

Which Key Factors Are Driving The Global Actinic Keratosis Market?

The market for actinic keratosis is driven by several factors, including increased access to healthcare services, infrastructure improvements in the healthcare system, and growing awareness of how climate change affects skin health. The market is expanding steadily as a result of all these factors.

What Are The Main Challenges Confronting The Actinic Keratosis Market Globally?

Several factors, such as high treatment costs, limited access to healthcare in developing regions, limited funding for research, and complexity in disease management, impede the growth of the actinic keratosis industry.

What Market Opportunities Exist For Actinic Keratosis Globally?

The factors creating opportunities for the actinic keratosis market include the emergence of customized therapeutics, incorporation of digital health solutions, application of artificial intelligence, and support for skin cancer screening initiatives.

Market Drivers

Multiple factors propel the actinic keratosis industry across the globe. The primary factors propelling the global actinic keratosis market are as follows:

Increased Frequency of Actinic Keratosis

A significant market driver is the incidence of actinic keratosis. In Australian individuals over forty, actinic keratosis is prevalent in 37% to 55% of cases, according to a 2019 article published by News-Medical.net, an AZoNetwork site. The Australian population, which has relatively pale skin, is connected to increased UV exposure. Australia is known for its outdoor activities. Therefore, people there usually spend as much time in the sun as possible before playing games. Actinic keratosis is associated with various risk factors, including time spent in the sun and total sun exposure. Still, it is also suggested that men are more likely than women to get it. Furthermore, the nationwide incidence of actinic keratosis is estimated to be 10.2% in females and 26.5% in males in the United States and the United Kingdom, respectively.

The market for actinic keratosis is predicted to expand due to the condition's rising prevalence, growing awareness of illness treatment options, and growing demand for minimally invasive treatments. Actinic keratosis therapy is becoming more and more necessary as people become more aware of the negative consequences of the condition. Moreover, government and nonprofit awareness campaigns play a major role in the growth of the market. Increasing R&D efforts should also help expedite the approval of novel medications for the treatment of actinic keratosis. In addition, there is a higher frequency of detection and treatment due to the elevated risk of skin cancer associated with actinic keratosis.

Market Restraints

There are several obstacles that the global actinic keratosis market must overcome to continue growing. Among them are the following:

Low Treatment Uptake and a Shortage of Skilled Workers

The most significant obstacles hindering the market expansion for actinic keratosis are insufficient availability of qualified experts and restricted treatment uptake in developing nations. Treatment for actinic keratosis involves surgical and medical specialists performing procedures like photodynamic therapy, cryotherapy, and chemical peels. However, it is anticipated that a severe shortage of general surgeons will impede the market expansion for actinic keratosis. Furthermore, it is anticipated that greater treatment costs and a lack of knowledge about the health issue in less wealthy countries may restrict market expansion. The rise of substitute natural therapies is anticipated to impede the expansion of the industry.

Opportunities

There are plenty of potential prospects in the global actinic keratosis industry. Among these are the following:

An Increase in Medication Approvals and the Introduction of Innovative Treatments

The market for actinic keratosis will continue to grow due to more drug approvals and the release of innovative treatments for the condition. The US Food and Drug Administration (FDA) has granted approval for new medications to treat actinic keratoses. Topical fluorouracil, imiquimod, diclofenac, ingenol mebutate, and pharmacological therapy combinations are some of these medications. Due to their easy availability, strong target specificity, and low risk of scarring, topical medicines hold a significant market share in the actinic keratosis market and are predicted to show a similar trend over the projected period. Additionally, the industry is significantly influenced by the widespread use of combination treatments and possible pipeline medications. Increased use and monetization of innovative drugs are other factors anticipated to boost market growth. The market for actinic keratosis will likely develop due to enhanced R&D efforts, which are expected to accelerate the approval of innovative drugs for the condition.

Competitive Landscape

Key Players

There are several major competitors in the fiercely competitive global actinic keratosis market. The following are a few of the leading market participants and their market shares:

• Almirall, S.A.
• Bausch Health Companies Inc.
• Perrigo Company plc.
• Sun Pharmaceutical Industries Ltd.
• Hill Dermaceuticals, Inc.
• Spear Pharmaceuticals
• Tolmar Pharmaceuticals, Inc.
• Bioforntera AG
• Cipher Pharmaceuticals Inc.
• Vidac
• Athenex, Inc.
• 3M
• Mayne Pharma Group Limited
• Others

To remain competitive, these companies prioritize product innovation, distribution channel expansion, mergers, and acquisitions.

The largest suppliers in the global actinic keratosis market continuously work to keep one step beyond the competition by developing innovative concepts and products.

In December 2022, In Finland, Biofrontera AG introduced AMELUZ on a commercial basis. As part of traditional photodynamic therapy or as daylight therapy, this product launch can be used in accordance with the European approval for the treatment of actinic keratoses and basal cell carcinoma using the BF-RhodoLED lamp. The company was able to improve both its geographic presence in the European Union and its range of products thanks to this strategy.

In September 2022, Actinic keratosis KX01 license number Wei-Bu-Yao-Shu-Zi No. 028364 was approved by Taiwan's Ministry of Health and Welfare (MOHW) for PharmaEssentia Corporation as a new drug application.

Summary of Key Findings

• During the projected period, the growing elderly population globally is expected to support market expansion.
• The market is segmented by treatment type, distribution channel, prescription status, patient type, age group, gender, and region.
• The most popular treatment type in the market is topical medications.
• Hospitals and clinics are the foremost distribution channel category.
• Regarding CAGR, prescription medications are expected to grow fastest during the forecast period.
• The category for adults will likely see the highest CAGR during the anticipated time frame.
• North America is leading market development; the market is highly competitive with key players including Almirall, S.A., Bausch Health Companies Inc., Perrigo Company plc., Sun Pharmaceutical Industries Ltd., Hill Dermaceuticals, Inc., Spear Pharmaceuticals, Tolmar Pharmaceuticals, Inc., Bioforntera AG, Cipher Pharmaceuticals Inc., Vidac, Athenex, Inc., 3M, Mayne Pharma Group Limited, and Others.

Future Outlook

• The actinic keratosis industry is expected to increase significantly in North America and has a positive outlook worldwide.
• Actinic keratosis can result in squamous cell carcinoma, a kind of skin cancer that is anticipated to accelerate the expansion of the actinic keratosis market.
• During the forecast duration, one of the main challenges expected to impede the growth of the actinic keratosis market is the high treatment costs.
• To stay ahead of the competition, key enterprises must develop new products, expand their market reach, and keep their prices competitive.

How CXOs Can Benefit from the Credence Research Actinic Keratosis Market Report

CXOs may get a detailed picture of the market in the Credence Research Actinic Keratosis Market Report, which includes:

• Market size and growth forecast: The report provides detailed estimates of the global actinic keratosis market size, segmented by treatment type, distribution channel, prescription status, patient type, age group, gender, and region. It also includes forecasts for the market through 2032 based on key trends and drivers.
• Market segmentation: The research report breaks down the market for actinic keratosis into segments based on the treatment type, distribution channel, prescription status, patient type, age group, gender, and region. This segmentation provides CXOs with a granular understanding of the market and the opportunities in each segment.
• Competitive landscape: The research report offers a detailed analysis of the major companies in the actinic keratosis industry, including information on their business plans, line of products, and earnings. CXOs can use this information to evaluate and identify their competitors.
• Key trends and drivers: The research report identifies and evaluates the main trends and factors influencing the market for actinic keratosis. CXOs can use this information to make well-informed choices regarding their plans and investments.

CXOs can use the insights from the Credence Research Actinic Keratosis Market Report to:

• Identify growth opportunities: With the help of this analysis, CXOs may identify new growth opportunities in the actinic keratosis sector. For example, the report identifies the growing demand for actinic keratosis from dermatology centers as a key opportunity.
• Make informed investment decisions: With the help of the report, CXOs can choose actinic keratosis wisely. For example, the research study provides information on the critical factors to consider while selecting actinic keratosis solutions and evaluating actinic keratosis suppliers.
• Develop competitive strategies: The research report can be used by CXOs to develop competitive strategies for their actinic keratosis businesses. For example, the research paper outlines the main strategies suppliers of actinic keratosis utilize to differentiate themselves from competitors.
• Track market developments: CXOs may stay ahead of the curve by tracking market developments with the aid of this research report. For instance, the research report offers insights into the most recent developments and trends in the market for actinic keratosis.

In general, CXOs seeking to expand their industry knowledge and spot growth prospects will find the Credence Research Actinic Keratosis Market Report a useful tool.

Segmentation

• By Treatment Type
  • Topical Medications
  • Photodynamic Therapy (PDT)
  • Cryotherapy
  • Laser Therapy
  • Chemical Peels
• By Distribution Channel
  • Hospitals and Clinics
  • Dermatology Centers
  • Retail Pharmacies
  • Online Retail
• By Prescription Status
  • Prescription Medications
  • Over-the-counter (OTC) Products
• By Patient Type
  • Outpatient Treatment
  • Self-administered Treatment
• By Age Group
  • Adults
  • Elderly
• By Gender
  • Male
  • Female
• By Region
  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • The U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Rising Prevalence of Actinic Keratosis

The increasing incidence of actinic keratosis, particularly among aging populations and individuals with high cumulative sun exposure, is directly expanding the patient pool requiring diagnosis and treatment. This trend is especially pronounced in regions such as North America, Europe, and Australia, where awareness and detection rates are high.

Advancements in Minimally Invasive Treatments

The development and adoption of minimally invasive therapies, such as photodynamic therapy (PDT) and advanced topical medications, are driving market growth by offering effective, patient-friendly alternatives to surgical procedures. These innovations improve patient compliance and outcomes, encouraging broader adoption in both outpatient and self-administered settings.

Expansion of Healthcare Infrastructure and Access

Improvements in healthcare infrastructure, particularly in emerging markets across Asia Pacific and Latin America, are increasing access to dermatological care and actinic keratosis treatments. Enhanced distribution channels, including hospitals, clinics, and online retail, are making therapies more widely available to diverse patient populations.

Regulatory Approvals and Product Launches

Frequent regulatory approvals and the introduction of new, targeted therapies by leading pharmaceutical companies are expanding the range of available treatment options. This not only stimulates competition but also accelerates market penetration and adoption of innovative products, such as new topical agents and combination therapies.

Growing Awareness and Early Detection Initiatives

Public health campaigns and educational initiatives are raising awareness about the risks of actinic keratosis and its potential progression to skin cancer. Increased screening and early detection efforts are leading to higher diagnosis rates and earlier intervention, further fueling demand for effective treatment solutions.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.